• Primogene

  Participated · Seed · Apr 2026

  Primogene develops and operates an enzymatic biomanufacturing platform to produce structurally complex biomolecules identical to their natural counterparts, including HMOs like DSLNT and difucosyllacto‑N‑tetraose I. The company manages the full value chain—enzyme development and production, biotransformation, and downstream processing—at its facility in Leipzig. It emphasizes enzymatic processes to overcome limitations of fermentation approaches and to enable scalable, cost‑efficient production of complex ingredients. Primogene holds an IP portfolio across several product categories and has established commercial partnerships in the personal care sector while pharmaceutical raw materials are in advanced customer evaluation. Founded in 2023, the company is expanding production capacity, growing its team, and seeking joint development partners among infant formula and functional food manufacturers. It is also collaborating with Fraunhofer IZI on infection‑prevention research and working with neonatal intensive care units to monitor HMO concentrations in breast milk.

• Meliodays Medical

  Participated · Seed · Nov 2025

  Founded in 2022 in Munich by Prof. Dr. Benjamin Wolf, Simone Sabbione and Martin Sabbione, Meliodays Medical is building MelioOne, a hormone-free, locally acting therapy that releases micro-doses of analgesics directly in the uterus to alleviate menstrual pain. The approach leverages a proven polymer technology, targeting pain at its source while avoiding systemic adverse effects associated with high-dose oral medications or hormones. Period pain affects about 80 % of menstruating people, with up to 30 % experiencing debilitating symptoms, and the company aims to restore their quality of life. Its platform could also be extended to indications such as endometriosis, and patent protection has already been secured in more than 150 countries. The start-up recently secured an oversubscribed pre-seed round exceeding €800 000, providing the resources to complete preparations for preclinical testing of its intra-uterine application. The infusion of capital underpins continued product development and early regulatory planning. To date, Meliodays Medical’s external funding stands at just over €800 000.

No current team members are available.